Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Telesis Bio is a synthetic biology company that provides automated benchtop solutions for DNA and mRNA synthesis, significantly accelerating the research and development cycle for life science organizations. The company's flagship BioXp™ system automates the synthesis, cloning, and amplification of DNA fragments and mRNA, enabling decentralized and rapid production of genomic materials. Formerly known as Codex DNA and SGI-DNA, the company supports critical applications in antibody discovery, vaccine development, and precision medicine. In 2024, Telesis Bio announced a strategic shift, including the sale of its BioXp® automation business to Novacyt to focus on its core synthetic biology intellectual property and Gibson Assembly® technology.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Telesis Systems.